Topical imiquimod and tumor necrosis factor (TNF)-a inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively. While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-a blockers to elicit cutaneous inflammatory reactions has only recently been recognized. We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association. To date, no relation has ever been suggested between TNF-a inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod. We believe that this subject deserves further analysis; meanwhile, increased attention should be drawn to the possibility of this adverse interaction, as simultaneous treatment with TNF-a blockers and imiquimod is becoming increasingly frequent in daily practice.
During the last decade, anti-tumor necrosis factor (TNF)-a agents have gained widespread acceptance as a safe and effective alternative to traditional immunosuppressant therapies in the management of several autoinflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis (PsA), and psoriasis (1) . Infliximab, a member of the TNF-a inhibitor class, is a chimeric monoclonal antibody capable ofbinding the soluble as well as the transmembrane form ofTNF-a. Despite exhibiting an overall favorable safety profile, anti-TNF-n biologics have been associated with a growing number of cutaneous side effects; many of the latter, including cutaneous lupus erythematosus (CLE), lichen planus (LP)-like reactions, erythema multiforme (EM), and paradoxical psoriasiform eruptions, appear to be primarily caused by disruption of the TNF-a1 interpheron (IFN)-a balance (2) (3) (4) .
Imiquimod, a Toll-like receptor (TLR)-7 and -8 agonist belonging to the imidazoquinoline family, has become a common non-surgical option for topical treatment of external anogenital warts, actinic keratoses, and superficial basal cell carcinomas (sBCC) (5) (6) . Imiquimod 5% cream was approved by the US Food and Drug Administration and the European Medicines Agency for treatment of small sBCC; using a qd5x .week regimen for 6 weeks, 5-year sustained clearance rates of 70 to 85% have been reported (5) (6) . Moreover, this agent has shown variable efficacy in several "off-label" indications, including nodular basal cell carcinomas (nBCC) (7) (8) . Imiquimod action primarily relies on activation ofa Thl-weighted cell-mediated cytotoxic immune response directed against virus-infected and neoplastic host cells (9) . Clinical efficacy of imiquimod is usually paralleled by the well-known development of application site reactions (ASRs), which in most cases are ofmild to moderate severity, allowing to complete 6-week treatment schedules as planned (10) .
We describe two patients receiving infliximab for psoriasis and PsA who developed exaggerated ASRs during treatment with topical imiquimod. Clinical data and course ofASRs are summarized in Table I .
Case Reports Patient 1
In February 2010 a 45-year-old woman was referred to our department for evaluation of a recently developed erythematous lesion on her right arm, which had been noted during the last follow-up visit for psoriasis; the patient could not recall the time of onset ofthe lesion, as the latter was asymptomatic and, in all likelihood, it had been previously dismissed as a psoriatic plaque. She had been suffering from psoriasis since 1993, with following development of articular disease. In the light of failures with past therapies (including narrowband-UVB, cyclosporine, and methotrexate), as well as severity of skin and joint involvement, she had been receiving infliximab since May 2006. Such treatment had led to rapid and sustained improvement of her condition; side effects had never been reported, nor had routine laboratory examinations (including peripheral blood count, urinalysis, and blood chemistries) ever revealed significant abnormalities. Her medical history was additionally significant only for endometriosis and mild insulin resistance; besides oral contraceptives, she denied having taken any additional oral medications during the previous 6 months.
On physical examination, a pinkish, partially ulcerated, roundish plaque was found on the right deltoid area, measuring 1.7xO.9cm ( Fig. la) . Dermoscopic features included shiny white to red structureless areas, short thin arborizing vessels, subtle blue-gray globules, and an area of ulceration ( Fig. 1b ). Based on clinical and dermoscopic findings, a diagnosis of sBCC was made (11) , and the patient was started on treatment with topical imiquimod 5% cream according to recommended schedule (qd 5x/week,for 6 weeks) (5) (6) .
After 20 days the patient presented to our department complaining ofa painful ulcer which had occurred at the site of imiquimod application. On clinical examination, a 3.5 x 2.0 em oval, punchedout ulcer was seen, featuring profuse exudation as well as erythematous induration of surrounding skin (Fig. Ic) ; the ulcer was centered where the sBCC had been previously detected, but was significantly larger in size. The patient was in otherwise good health, no fatigue nor flu-like symptoms were reported, and psoriasis continued to be well controlled. According to the patient, the adverse reaction dated back to as early as after 4 days of imiquimod application, starting as an erythematous plaque; weeping and ulceration had ensued after approximately 1 week. She denied applying imiquimod under occlusion. Despite our previous recommendations to suspend topical imiquimod in case any significant adverse event occurred, she had continued adhering to the planned treatment schedule. Accordingly, imiquimod was discontinued and the patient was dismissed with topical application of zinc oxide paste.
The ulcer underwent crusting and subsequent healing within 1 month. At the follow-up visit after 4 months, clinical examination of the right arm revealed an oval area of scarring, with a maximum diameter on.Ocm (Fig. Id) . Dermoscopic evaluation confirmed this finding; no residual signs suggestive of sBCC were detected.
Patient 2
In April 2010 a 68-year-old man presented to our department with a pigmented plaque of at least 6 months duration on his left shin; the lesion had already received a diagnosis of nBCC, and previous treatment with MAL-PDT had proved unsuccessful.
He had been undergoing treatment with infliximab for psoriasis and PsA for 42 weeks; due to exacerbation of articular symptoms, weekly administrations of7.5 mg methotrexate SC had been successfully added since November 2009. Both psoriasis and PsA were under control, and routine laboratory measurements were unremarkable. His medical history was significant for supraventricular parossistic tachycardia and diverticulosis; at that time, his oral medication record included bisoprolol, flecainide acetate, acetylsalicylic acid, and lansoprazole. Clinical and dermoscopic evaluation confirmed a diagnosis of nBCC; in view of the patient's significant comorbidities, a conservative strategy was pursued, and therapy with topical imiquimod 5% cream (qd 5x/week for 6 weeks) was started.
After 5 days of scheduled treatment, the patient experienced the development of a painful, weeping, erythematous plaque at the site of imiquimod administration, together with multifocal ulcerations; on day 10, he autonomously suspended imiquimod and presented to our department. On physical examination, the inflamed area extended well beyond previous nBCC borders. After a further 7 days, during which the lesion was treated with zinc oxide paste alone, an attempt was made to resume imiquimod administration; severe exacerbation of inflammation promptly ensued, exhibiting features analogous to that of the previous reaction. Topical treatment was definitively interrupted and the patient was referred to the dermato-surgery unit; histopathologic examination of excisional biopsy specimen led to a final diagnosis of nBCC with adenoid features.
DISCUSSION
The immune response modifier imiquimod represents a valuable option for topical treatment of non-melanoma skin cancer (NMSC), especially in patients unable or unwilling to undergo surgical therapy (5) (6) (7) (8) . Mild to moderate ASRs (including erythema, edema, weeping , erosions, crusting, and hypopigmentation) are common and well documented: typically, imiquimod ASRs reach their zenith after 4-5 weeks and often require short rest period s (5-6, 10), occasionally spreading to involve apparently healthy, but chronicall y sun-damaged skin (6) . Nevertheless, scheduled treatment can be usually resumed and completed after rest periods ; true ulceration followed by scarring has been reported in less than 20% of treated patients (5-6, 10). We describe two cases of exaggerated ASRs to topical imiquimod in the setting of systemic anti-TNF-Q therapy. Our cases were significant for several reasons : the ASRs developed as early as during the first week of imiquimod treatment , with rapid evolution to frank ulceration, resulting in permanent scarring. Such features were more evident in patient 1, who adhered to scheduled therapy for a further 2 weeks after onset of inflammation; by contrast, topical treatment was suspended earlier in patient 2, but the ASR rapidly recurred at a subsequent attempt to reintroduce imiquimod. Furthermore, in both cases the ASRs involved an area significantly wider than pre-existing BCC size, as well as devoid of features of chronic sun-damage.
A potential side effect of topical imiquimod in psoriatic patients is psoriasis exacerbation, both at the treated area and at distant, previously unaffected sites (12) . We can exclude the occurrence of such phenomenon in our patients for several reasons : ulceration was a striking feature of reaction s at the treated sites, no typical findings of psoriasis were seen, nor did new psoriatic lesions develop elsewhere.
Imiquimod anti-tumoral. effect is primarily mediated by activation of plasmacytoid dendritic cells (pDCs), followed by release of significant levels of IFN-a, among a wide range of different cytokines and chemokines (9, 12) . pDCs are a rare cell population specialized in producing type I IFNs, acting at the interface and as a link between innate and adaptive immunity (13) (14) . Upon appropriate stimuli, including TLR-7 activation, pDCs undergo maturation and produce large amounts of IFNa, prompting myeloid dendritic cells to induce a Thl-skewed cellular immune response (13) (14) (15) ; in addition, a direct, "professional" cytotoxic activity against abnormal keratinocytes (KCs) was recently attributed to pDCs (15) (16) .
PDCs and IFN-a have emerged as key players in the pathogenesis ofseveral histopathologic models of "interface dermatitis" (including CLE, EM, and LP), with observed amount of pDCs paralleling severity of inflammatory infiltrates as well as intensity of interface dermatitis histopathologic hallmarks (13) (14) (15) (16) (17) . Interestingly, the histopathologic picture of imiquimod ASRs was recently demonstrated to exhibit classical features of interface dermatitis, including lichenoid lymphocytic infiltrate, vacuolar alteration along the dermo-epidermal junction, and scattered apoptotic KCs in the epidermis (18) .
To our knowledge, no link has ever been suggested between treatment with anti-TNF-a agents and an increased proneness towards developing severe imiquimod ASRs. TNF-a inhibitors, however, have been associated with a progressively wider and heterogeneous spectrum of cutaneous adverse reactions (2) (3) (4) (19) (20) . A subgroup of the latter, including those having clinical and/or histopathologic features of CLE, EM, LP, and, paradoxically, psoriasis, seems to pathogenetically hinge on pDC hyper-activation; this concept would be supported by evidence of lesional inflammatory infiltrates showing an "IFN-a signaling signature" as well as increased CD8+ICD4+ ratios (4, (21) (22) . To date, it has not been understood why only a minority of patients developed any of these anti-TNF-a-induced reactions in general, and any specific clinico-pathological variants in particular. It seems likely that the common setting of systemic TNF-a inhibition always plays a key role, whereas currently unresolved differences in signaling cascades would account for small rates of affected patients as well as observed variances in clinicopathological outcomes (4, 21, 23) .
TNF-a acts as a negative regulator of IFN-a release by hindering both the generation ofnew pDC precursors and the production of IFN-a by mature pDCs; systemic TNF-a inhibitor administration is associated with increased plasma levels ofIFN-alpha (21) (22) (23) (24) .Accordingly,treatment with TNF-a blockers might disrupt a fine-tuned cytokine homeostasis, leading to lower thresholds of pDC activation and IFN-a up-regulation (21, 23) . As a consequence, patients under treatment with anti-TNF-a agents might show increased susceptibility to developing IFN-a-dependent inflammatory reactions.
No clear event precipitating TNF-a blockers cutaneous eruptions has yet been identified (2, 4, (19) (20) (21) (22) ; on the contrary, the triggers of our cases were seemingly manifest (topical imiquimodin the presence of a population of neoplastic KCs, both factors conjunctively prompting release of IFN-a), with the reactions always being limited to areas of application and sparing any distant sites.
We recognize that the number of reported cases is very limited, and that a larger cohort of patients is needed to substantiate any hypotheses; the described ASRs are still attributable to chance, as in a minority of patients topical treatment ofNMSC with imiquimod may lead to significant ulceration and even scarring (5) (6) 10) . Nevertheless, several features of our cases, including early time of onset, severity of clinical picture, and spatial extension beyond BCC borders, were remarkable and might not be a coincidence. If our hypothesis is true, the described reactions to imiquimod followed the conventional pDCs-IFN-a-cytotoxic T-cell response pathway, albeit to an exaggerated degree; thus, further histopathological or molecular analyses in all probability would have failed to add any significant information. Based on these findings, together with a reasonable pathogenetic basis, the potential for an increased risk of severe and atypical imiquimod ASRs in patients receiving infliximab should be considered. We believe that such susceptibility, if confirmed, might also affect patients under treatment with other anti-TNF-a biologics, including etanercept, adalimumab, and certolizumab, thus standing as a possible TNF-a inhibitor class effect (2) . Of note, chronic sun exposure, PUVA therapy, and use of systemic immunomodulatory drugs may all increase the risk of NMSC in psoriatic patients, while anti-TNF-a agents are becoming the mainstay in the long-term management of psoriasis and PsA (I, 25); thus, the concomitant administration of topical imiquimod and TNF-a antagonists may be an increasingly common scenario in clinical practice.
In conclusion, we report two cases ofexaggerated ASRs to imiquimod in the context of systemic TNFainhibition; although the small number of patients is insufficient to rule out a fortuitous occurrence, our cases suggest that treatment with TNF-a blockers may predispose to the risk of developing severe, atypical ASRs to topical imiquimod; as for other cutaneous adverse reactions to anti-TNF-a agents, unbalance in the pDCs-IFN-a axis regulation might be responsible. Thus, we believe that this topic merits further study, as concomitant treatment with TNF-a blockers and topical imiquimod may become more and more frequent in daily practice; meanwhile, dermatologists should be aware of the possibility of this previously unreported adverse interaction.
